Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
81 hedge funds and large institutions have $660M invested in Audentes Therapeutics, Inc in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
61% more capital invested
Capital invested by funds: $409M → $660M (+$251M)
16% more funds holding
Funds holding: 70 → 81 (+11)
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.1M |
| 2 |
AG
Artal Group
Luxembourg
|
+$4.34M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$3.3M |
| 4 |
Morgan Stanley
New York
|
+$2.88M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.13M |
| 3 |
BlackRock
New York
|
-$5.06M |
| 4 |
DM
Deerfield Management
New York
|
-$4.43M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$3.7M |
BOLD Hedge Fund Activity: Q3 2017 in Review
81 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q3 2017, worth a combined $660M — up 61% from $409M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BOLD positions and 6 closed out — a net gain of 12 holders — while 24 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $64.1M. The largest seller was OrbiMed, cutting an estimated $14.6M.
- 81 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q3 2017, up from 70 in Q2 2017.
- Funds reported $660M of Audentes Therapeutics, Inc stock for Q3 2017, up 61% quarter-over-quarter.
- 18 funds opened new Audentes Therapeutics, Inc positions in Q3 2017 and 6 closed out, a net change of +12 holders.
- The largest Audentes Therapeutics, Inc buyer in Q3 2017 was Fidelity Investments, an estimated $64.1M added.
- The largest Audentes Therapeutics, Inc seller in Q3 2017 was OrbiMed, an estimated $14.6M sold.
Based on aggregated 13F filings for Q3 2017.